Xueyong Li

Dr. Xueyong Li

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2023 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
XLXueyong Li
Xueyong Li
YCYu Cheng
Yu Cheng
BCBo Chen
Bo Chen
YCYiying Chen
Yiying Chen
YHYingbin Huang
Yingbin Huang
HQHongqiang Qiu
Hongqiang Qiu

7 May 2025 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
XLXueyong Li
Xueyong Li
LZLili Zhou
Lili Zhou
DWDanjie Wang
Danjie Wang
QWQiong Wu
Qiong Wu
XHXuanxi Huang
Xuanxi Huang
YCYu Cheng
Yu Cheng
Polymyxin B (PMB) remains a last-line therapeutic agent for multidrug-resistant gram-negative bacteria (MDR-GNB) infections. However, reliable pharmacokinetic (PK) data to guide nebulized PMB dosing regimens in critically ill patients are limited. This study aimed to establish a population pharmacokinetic (PopPK) model for PMB in both epithelial lining fluid (ELF) and plasma of critically ill patients with MDR-GNB pneumonia and to optimize dosing regimens. A prospective PK study was conducted in 76 adult patients receiving nebulized PMB either as monotherapy or in combination with intravenous administration. PK data were analyzed using non-linear mixed-effect modeling, with PMB concentration–time profiles described by a coupled model integrating separate two-compartment models for plasma and ELF. The final model identified albumin levels and age as significant covariates influencing PK variability. Monte Carlo simulations demonstrated that nebulization therapy either alone or combined with intravenous administration significantly enhances ELF concentration and the probability of target attainment. Additionally, Pseudomonas aeruginosa requires higher nebulized doses than Klebsiella pneumoniae and Acinetobacter baumannii . This study develops a PopPK model of PMB in ELF and plasma, providing critical insights to optimize PMB treatment strategies for patients with MDR-GNB pneumonia.

28 October 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
XLXueyong Li
Xueyong Li
BZBingqing Zhang
Bingqing Zhang
YCYu Cheng
Yu Cheng
MCMaohua Chen
Maohua Chen
HLHailing Lin
Hailing Lin
HQHongqiang Qiu
Hongqiang Qiu
Polymyxin B (PMB) is the final option for treating multidrug-resistant Gram-negative bacterial infections. The acceptable pharmacokinetic/pharmacodynamic target is an area under the concentration–time curve across 24 h at a steady state (AUCss,24h) of 50–100 mg·h/L. The limited sampling strategy (LSS) is useful for predicting AUC values. However, establishing an LSS is a time-consuming process requiring a relatively dense sampling of patients. Further, given the variability among different centers, the predictability of LSSs is frequently questioned when it is extrapolated to other clinical centers. Currently, limited data are available on a reliable PMB LSS for estimating AUCss,24h. This study assessed and validated the practicability of LSSs established in the literature based on data from our center to provide reliable and ready-made PMB LSSs for laboratories performing therapeutic drug monitoring (TDM) of PMB. The influence of infusion and sampling time errors on predictability was also explored to obtain the optimal time points for routine PMB TDM. Using multiple regression analysis, PMB LSSs were generated from a model group of 20 patients. A validation group (10 patients) was used to validate the established LSSs. PMB LSSs from two published studies were validated using a dataset of 30 patients from our center. A population pharmacokinetic model was established to simulate the individual plasma concentration profiles for each infusion and sampling time error regimen. Pharmacokinetic data obtained from the 30 patients were fitted to a two-compartment model. Infusion and sampling time errors observed in real-world clinical practice could considerably affect the predictability of PMB LSSs. Moreover, we identified specific LSSs to be superior in predicting PMB AUCss,24h based on different infusion times. We also discovered that sampling time error should be controlled within −10 to 15 min to obtain better predictability. The present study provides validated PMB LSSs that can more accurately predict PMB AUCss,24h in routine clinical practice, facilitating PMB TDM in other laboratories and pharmacokinetics/pharmacodynamics-based clinical studies in the future.

16 April 2024 in Journal of Pharmacokinetics and Pharmacodynamics
Verified
Journal Article
Closed access
PDF file
XLXueyong Li
Xueyong Li
YCYu Cheng
Yu Cheng
BZBingqing Zhang
Bingqing Zhang
BCBo Chen
Bo Chen
YCYiying Chen
Yiying Chen
HQHongqiang Qiu
Hongqiang Qiu

5 November 2025 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
BCBo Chen
Bo Chen
YCYiying Chen
Yiying Chen
MCMing Chen
Ming Chen
YMYunyi Mao
Yunyi Mao
YHYingbin Huang
Yingbin Huang
HQHongqiang Qiu
Hongqiang Qiu
This study aimed to develop population pharmacokinetic (PopPK) models for intravenous sulfamethoxazole (SMX) and trimethoprim (TMP) to optimize dosing regimens for the treatment of Pneumocystis jirovecii pneumonia using these models. A prospective study was conducted in 79 patients treated with intravenous trimethoprim-sulfamethoxazole. PopPK models were developed using nonlinear mixed-effect modeling to evaluate the effects of liver function, kidney function, and genetic polymorphisms ( NAT2 and CYP2C9 ) on pharmacokinetic parameters. Monte Carlo simulations were employed to identify the optimal dosing regimen. Pharmacokinetic analysis of SMX and TMP included 232 post-dose plasma concentrations from 79 adult patients. A one-compartment model with first-order elimination best described the data. Creatinine clearance (CrCL) was significantly correlated with the pharmacokinetic parameters of both SMX and TMP, while continuous renal replacement therapy significantly influenced only the SMX model. Liver function, NAT2 , and CYP2C9 genotypes did not exhibit statistically significant effects on the models. Co-trimoxazole 50 mg/kg/day in a three-times-daily divided dose regimen is feasible for patients with CrCL of <15 mL/min. However, in patients with normal renal function, the guideline-recommended 90 mg/kg/day dose demonstrates a risk of supratherapeutic exposure. This study provides critical pharmacokinetic insights into SMX and TMP for patients, highlighting the necessity for dose adjustments in those with renal dysfunction. The currently recommended dosing regimens in clinical guidelines pose a risk of excessive drug exposure. Our study offers a more precise dosing strategy to optimize treatment efficacy and safety.

1 January 2026 in International Journal Of Clinical Practice
Verified
Journal Article
Open access
YHYingbin Huang
Yingbin Huang
TLTing Liu
Ting Liu
BLBin Li
Bin Li
FDFenfang Dong
Fenfang Dong
XLXueyong Li
Xueyong Li
ZZZhichang Zhao
Zhichang Zhao
Background: Hypervirulent Klebsiella pneumoniae (hvKP) has emerged as a critical public health concern due to its propensity to cause life‐threatening invasive infections, often leading to fatal outcomes. This study aims to systematically reveal the current research status of hvKP, outline key developmental trends in the field, and establish a theoretical foundation for future investigations. Methods: Published hvKP research data were analyzed through systematic processing. Academic literature was extracted from scientific databases (PubMed, Scopus, and Web of Science), followed by data preprocessing using Python‐based computational tools and visualization of research outputs, geographic distribution, citation collaboration networks, and keyword analysis. Results: The final analytical dataset included 782 documents published between 2005 and 2024, comprising 678 articles, 55 reviews, and 49 other document types. China recorded the highest publication output ( n = 410) with significant citation impact, demonstrating a central coordinating role in global research networks via visual cluster analysis. Russo Thomas A exhibited the greatest academic influence, with his article achieving the highest citation count ( n = 267). Bibliometric analysis highlights that explorations of drug resistance mechanisms, pathogenic mechanisms, efficient diagnostic techniques, and novel therapeutic approaches are promising directions in this field. Conclusions: The annual growth of scientific publications and co‐author networks indicates that hvKP research has garnered significant global attention, emerging as a promising research domain. Combined with the steady expansion of research scopes, these trends reflect the scientific community’s urgent need to consolidate existing knowledge and identify research priorities.